CN Patent

CN101080225A — 包含替米沙坦及氢氯噻嗪的组合治疗

Assigned to Boehringer Ingelheim International GmbH · Expires 2007-11-28 · 18y expired

What this patent protects

本发明是关于一种药物组合物，其包含约80mg替米沙坦及约25mg氢氯噻嗪或约160mg替米沙坦及约50mg氢氯噻嗪，以用于治疗在以血管紧张素II受体拮抗剂或以血管紧张素II受体拮抗剂与低剂量氢氯噻嗪的药物组合物进行治疗后血压降低不足的病人的高血压。

USPTO Abstract

本发明是关于一种药物组合物，其包含约80mg替米沙坦及约25mg氢氯噻嗪或约160mg替米沙坦及约50mg氢氯噻嗪，以用于治疗在以血管紧张素II受体拮抗剂或以血管紧张素II受体拮抗剂与低剂量氢氯噻嗪的药物组合物进行治疗后血压降低不足的病人的高血压。

Drugs covered by this patent

Patent Metadata

Patent number
CN101080225A
Jurisdiction
CN
Classification
—
Expires
2007-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.